Sino-US Saiaojin Tumor Chain Group (including US Saiaojin Group and Sino-US Saiaojin Group) was founded in 1988. It is the first large-scale multinational medical and health industry group in China that focuses on the simultaneous development of "national physical and mental health". Since its establishment, the group has always taken "benefiting public health" as its mission and "achieving sound body" and "happy mind" as its core goals. With four decades of deep exploration in the medical and health field, it has built a full industrial chain layout covering investment, medical treatment, pharmaceuticals, education, scientific research, biotechnology development, and traditional Chinese medicine research and development. It brings together top technical talents in the medical field from both China and the United States, and provides professional health services to thousands of households worldwide with exquisite and advanced diagnostic and treatment technologies as well as high-quality medical devices and products.

Relying on 40 years of professional medical experience and 20 years of new drug research and development, the group has established a global medical service network, encompassing eight core alliances: the American Saiaojin Tumor Hospital Alliance, Zhengzhou Yumei Tumor Hospital International Alliance, Guangzhou Saiaojin Tumor Hospital International Alliance, Shenzhen Saiaojin Tumor Hospital International Alliance, Beijing Saiaojin Tumor Hospital International Alliance, Hainan Boao Saiaojin Tumor Hospital International Alliance, Wuhan Mingyi Saiaojin Tumor Hospital International Alliance, and Beidaihe Saiaojin Tumor Hospital International Alliance. This has formed an integrated service pattern featuring "global linkage and nearby diagnosis and treatment". At the same time, the group has established comprehensive strategic partnerships with well-known medical institutions worldwide, sharing advanced global diagnostic and treatment technologies to provide comprehensive support for Chinese patients seeking medical treatment overseas.

Scientific research and innovation are the core competitiveness of the group's development. Its subsidiary, Saiongen Group, headquartered in Los Angeles, USA, is a unicorn-type biotechnology enterprise specializing in molecular biology, cell research, and clinical diagnosis and treatment applications. It has established long-term strategic research partnerships with world-leading research institutions such as Harvard University, Yale University, Massachusetts Institute of Technology, University of Southern California, and Stanford University. Leveraging internationally leading core cell biotechnology, the group has obtained multiple world-class patents and won the "McEwen Innovation Award" (Nobel-level), the highest award of the World Stem Cell Society. Among them, the technology of inducing massive proliferation of neutrophils and macrophages in vitro from hematopoietic progenitor cells is recognized by the industry as a world-class breakthrough new technology.

To enhance its ability to transform scientific research into practical applications, the group has continuously invested in the biotechnology sector. Its biotechnology division encompasses multiple core enterprises such as the American SaioGen Cell Gene Therapy Company and Beijing Meio SaioGen Biotechnology Co., Ltd., establishing a comprehensive research and development as well as transformation system. Across three locations in China and the United States, the group has established six high-standard laboratories covering an area of over 20,000 square meters. These laboratories are capable of conducting the entire process of cell research and development, production, preparation, and storage. Currently, the group is undertaking multiple cell technology research and development projects and has established clinical research collaborations with numerous international and domestic hospitals, achieving deep integration between scientific research and clinical practice.

The group has achieved remarkable results in the transformation of scientific research achievements. ZMPB-NK006, developed by Hebei Meio Saiaojin Biotechnology Co., Ltd., a subsidiary of the group, has successfully obtained the clinical trial approval (IND) from the National Medical Products Administration as the first domestic innovative off-the-shelf NK cell drug for advanced or metastatic solid tumors. This product, through industrial mass production, has achieved a major breakthrough in inclusive immunotherapy. It is the first national-level IND for a specific NK immune cell drug specifically designed to treat various solid tumors and refractory tumors in China, bringing new hope for survival to patients with advanced solid tumors. In addition, the group has also made significant breakthroughs in the field of biological breeding, providing strong support for the protection and utilization of genetic resources of local chicken breeds in China.

The group has established six core business segments, covering oncology chain, cell biology, biopharmaceuticals, medical universities, medical groups, and public welfare and charity, forming an integrated development pattern of "industry-university-research-application". At the same time, it boasts six global immune cell tumor clinical research centers, comprehensively promoting clinical research and technology transformation in the field of immune cell tumors, and contributing to the high-quality development of the global cancer treatment industry.

In the future, the Sino-US Saiaojin Tumor Chain Group will continue to adhere to its original aspiration, deepen Sino-US scientific research and medical cooperation, promote the implementation and transformation of more scientific research achievements, and leverage its full industry chain advantages and international top-notch technology to provide higher-quality and more affordable medical and health services to patients worldwide, thereby contributing to the realization of the health vision of "healthy body and happy mind".